Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

此次批准主要基于Omvoh在3期VIVID-1研究中的积极结果。该研究针对中度至重度活动性克罗恩病患者，这些患者对糖皮质激素、免疫调节剂和/或生物 ...

Omvoh® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn’s ...

今日，礼来宣布，美国FDA已经批准Omvoh（mirikizumab）用于治疗成人中度至重度活动性克罗恩病（CD）。 这是继Omvoh于2023年10月首次获得FDA批准后的第二 ...

智通财经APP获悉，礼来(LLY.US)周一公布的研究结果显示，Mirikizumab(商品名Omvoh)对溃疡性结肠炎(UC)和克罗恩病具有长期疗效。该制药商声称，根据两项 ...

--Eli Lilly and Company announced today that the U.S. Food and Drug Administration has approved Omvoh™ infusion/ injection, the first and only interleukin-23p19 antagonist for the treatment of ...

Lilly has also submitted marketing applications for Omvoh in Crohn's disease around the globe, including in the European Union and Japan. Additional global regulatory submissions are planned.

Lilly's first approved treatment for a type of inflammatory bowel disease INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug ...